TABLE OF CONTENTS

HIGHLIGHTS

Selected Articles from This Issue

SPECIAL FEATURES

CCR Translations

Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma
Florian Castet, Catherine E. Willoughby, Philipp K. Haber, and Josep M. Llovet
See related article, p. 1836

Pressurized Intraperitoneal Aerosol Chemotherapy: The Road from Promise to Proof
Loek A.W. de Jong, Nielka P. van Erp, and Lana Bijelic
See related article, p. 1875

Morning for Irofulven, What Could be fiNER?
Haoyang Jiang and Roger A. Greenberg

CCR Drug Updates

FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
See related commentary, p. 1827

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

RESEARCH BRIEFS: CLINICAL TRIAL BRIEF REPORTS

Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer
Giulia Petroni, Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen-Kiang, Silvia C. Formenti, and Lorenzo Galluzzi

CLINICAL TRIALS: TARGETED THERAPY

Preclinical Evaluation and Phase Iib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejue Wang, Aimee Bence Lin, and Manish R. Patel
TABLE OF CONTENTS

1875 PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases
Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan Ho, Asim Shabbir, Maria V. Babak, Wee Han Ang, Boon Cher Goh, Wei Peng Yong, Lingzhi Wang, and Jimmy B.Y. So
See related commentary, p. 1830

1882 Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE)
Simon J. Crabb, Sarah Danson, James W.F. Catto, Syed Hussain, Danna Chan, Denise Dunkley, Nichola Downs, Ellicie Marwood, Laura Day, Geoff Saunders, Michelle Light, Amy Whitehead, Deborah Ellis, Naveed Sarwar, Deborah Enting, Alison Birtle, Bernadette Johnson, Robert Huddart, and Gareth Griffiths

1893 Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Mina M. Tayari, Helena G. Dos Santos, Deukwoo Kwon, Terrence J. Bradley, Amber Thomassen, Charles Chen, Yvonne Dinh, Aymee Perez, Arthur Zelent, Lluis Morey, Luisa Cimmino, Ramin Shiekhattar, Ronan T. Swords, and Justin M. Watts

CLINICAL TRIALS: IMMUNOTHERAPY

1904 Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors
Kyrakos P. Papadopouloas, Karen Autio, Talia Golan, Konstantin Dobrenkov, Elliot Chartash, Quisheng Chen, Richard Wnek, and Georgina V. Long

1912 Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma
David W. Andrews, Kevin D. Judy, Charles B. Scott, Samantha Garcia, Larry A. Harshyne, Lawrence Kenyon, Kiran Talekar, Adam Flanders, Kofi-Buaku Atsina, Lyndon Kim, Nina Martinez, Wenyin Shi, Maria Werner-Wasik, Haisong Liu, Mikhail Prosnaiak, Mark Curtis, Rhonda Kean, Donald Y. Ye, Emily Bongiorno, Sami Sauma, Mark A. Exley, Kara Pigott, and D. Craig Hooper

1923 Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, and Joseph Chao

PRECISION MEDICINE AND IMAGING

1932 PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes
Travis Shaffer, Arutselvan Natarajan, and Sanjiv S. Gambhir

1941 Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy
Paola Cluaser, Barbara Krug, Hubert Bickel, Matthias Dietzel, Katja Pinker, Victor-Frederic Neuhous, Maria Adele Marino, Marco Moschetta, Nicoletta Troiano, Thomas H. Helbich, and Pascal A.T. Baltzer

1949 Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Mirella L. Altoe, Kevin Kalinsky, Alessandro Marone, Hyun K. Kim, Hua Guo, Hanina Hibshoosh, Mariella Tejada, Catherine D. Crew, Melissa K. Accordino, Meghna S. Trivedi, Dawn L. Hershman, and Andreas H. Hielscher

1967 Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
TABLE OF CONTENTS

2074  Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance
Lir Beck, Michal Harel, Shun Yu, Ettai Markovits, Ben Boursi, Gal Markel, and Tamar Geiger

2087  Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells
Wenting Pan, Zhouwei Zhang, Hannah Kimball, Fangfang Qu, Kyler Berlind, Konrad H. Stopsack, Gwo-Shu Mary Lee, Toni K. Choueiri, and Philip W. Kantoff

2100  A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer
Alex Cazes, Oscar Betancourt, Edgar Esparza, Evangeline S. Mose, Dawn Jaquish, Eric Wong, Alexis A. Wascher, Hervé Tiriac, Marco Gymnopoulos, and Andrew M. Lowy

2111  Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001

LETTERS TO THE EDITOR

2119  Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Letter
Chuanxi Zheng, Li Min, and Chongqi Tu

2120  Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response
Olivier Mir, Charles Honoré, Ali N. Chamseddine, Matthieu Faron, Leila Haddag-Milani, Arnaud Bayle, and Axel Le Cesne

ABOUT THE COVER

The cover shows a section of pancreatic cancer precursor lesions in a mouse model of this disease expressing oncogenic Kras and the Sonic Hedgehog ligand. Gomori trichrome stain shows collagen deposition in blue, cell nuclei in dark purple, and cell cytoplasm in pink. For details, see the article by Steele and colleagues on page 2023 of this issue.